Frontiers in Psychiatry
November 12, 2021
Julia Bornemann, James B. Close, Meg J. Spriggs et al.
43 citations
Eleven individuals with chronic pain who self-medicate with psychedelic drugs described their experiences in a group discussion. Pain scores improved substantially during and after psychedelic experiences across a range of substances and doses. Two processes—Positive Reframing and Somatic Presence—were reliably identified as contributing to improvements in mental wellbeing, relationship with pain, and physical (dis)comfort. Additional strategies such as mindfulness, breathwork, and movement were also widely reported. The authors note that due to the subjective nature of the data, no claims on causality or generalisability can be made. These results will inform the design of a forthcoming controlled trial testing psychedelic therapy for chronic pain.
Frontiers in Psychiatry
September 30, 2021
James B. Close, Julia Bornemann, Maria Piggin et al.
21 citations
A co-designed guide for patient and public involvement (PPI) in psychedelic research addresses the lack of field-specific frameworks. Core values—trust, learning, purpose, and inclusivity—emerged from a workshop with public collaborators. The guidance aims to help researchers plan, evaluate, and improve PPI so that research is done with and by the public rather than on them, strengthening accountability and relevance as the field grows.
Frontiers in Psychology
May 11, 2023
Hannah Thurgur, Meg J. Spriggs, Ashleigh Murphy-Beiner et al.
13 citations
A framework called Access, Reciprocity and Conduct (ARC) is proposed to build an ethical and equitable infrastructure for psychedelic-assisted therapy (PAT). ARC rests on three pillars: ensuring equal access to PAT for those needing mental health treatment, promoting safety for those delivering and receiving therapy, and respecting traditional and spiritual uses of psychedelic medicines. The framework is being developed through a dual-phase co-design approach, first co-creating ethics statements with stakeholders from research, industry, therapy, community, and Indigenous settings, then inviting broader collaborative review. The authors aim to spark dialogue and help organizations and practitioners address complex ethical questions in PAT.
Frontiers in Psychiatry
June 4, 2024
Julia Bornemann, James B Close, Kirran Ahmad et al.
11 citations
Psilocybin-assisted therapy may help treat fibromyalgia, a chronic widespread pain condition with limited treatment options. A protocol describes a mechanistic study with 20 participants who will attend 8 visits over 8 weeks, including two dosing sessions where psilocybin is given at least once, with doses up to 25 mg. The primary focus is on brain mechanisms, measured via electroencephalography during the acute psychedelic state and magnetic resonance imaging before and after treatment. Primary outcomes are Lempel-Ziv complexity from EEG and experiential avoidance via questionnaire. Secondary measures include pain, physical and mental function, and additional neuroimaging. Results aim to clarify how psilocybin-therapy works in the brain and inform a future randomized controlled trial.
December 4, 2025
Avery Ostrand, Matthew M. Nour, Christopher Timmermann et al.
2 citations
preprint
The term 'psychedelic' was coined in 1956 from Greek roots meaning 'soul-manifesting' or 'soul-illuminating,' intended to name a drug category defined by its ability to induce a characteristic subjective state. This study examined the main subjective effects of psilocybin, ketamine, and MDMA. Over two hundred participants rated items about their experiences with all three drugs. Factor analyses revealed three or four independent dimensions of subjective experience. A machine learning classifier successfully predicted which drug a person had taken from the effects reported, confirming that the three drugs produce categorically distinct experiences: psilocybin induces visions and psychological insight, ketamine induces dissociation, and MDMA induces pro-social feelings such as love. Psilocybin is thus an exemplar psychedelic drug, definable by its induction of a psychedelic state characterized by visions and insight.